Our 2023 Annual Report features stories about our people, highlighting advances in our research, clinical, and educational missions. We share how an anonymous donor’s generous gift will help advance our prostate cancer research programs, and other exciting news!
Read Select Articles form the Report:
Philanthropy Moves the Needle on Creating Novel Therapies for Prostate Cancer
A generous donor, who wishes to remain anonymous, hopes to move the needle on prostate cancer research at Duke. Their $1 million gift in the form of unrestricted funds for prostate cancer research, will support the work of Jiaoti Huang, MD, PhD, Johnston-West Endowed Department Chair of Pathology, to conduct prostate cancer research in partnership with the Duke Cancer Institute’s (DCI) Center for Prostate and Urologic Cancers.
In Pursuit of Personalized Treatment Strategies: Dr. Ling Cai
One of the newest members of Duke Pathology’s team, Ling Cai, PhD, is focused on developing innovative, therapeutic approaches for advanced prostate cancer.
A Simple Approach to Complex Discoveries in Metastasis: Dr. Ming Chen
Ming Chen, PhD, is leading groundbreaking research to reshape our understanding of cancer biology.
Outsmarting Prostate Cancer's Evasive Cells: Dr. Jiaoti Huang
Since joining Duke in 2016, Jiaoti Huang, MD, PhD, has been a pivotal leader, mentor, and scientist. As an internationally renowned surgical pathologist and prostate cancer researcher for over 20 years, Huang is a leading authority in studying molecular mechanisms, biomarkers, and novel therapeutics for prostate cancer.
Searching for Druggable Targets: Dr. Everardo Macias
In his inaugural independent role, Everado Macias, PhD, has demonstrated his invaluable contributions to Duke Pathology by spearheading compelling research initiatives, solidifying his position as a leader in the field.
Shining a Light on Cell Transformation with 3D Technology: Dr. Jung Wook Park
Jung Wook Park, PhD, is at the forefront of innovative research in prostate cancer. Motivated by childhood curiosity and a familial encounter with pancreatic cancer, Park's journey led him to explore the intricacies of cancer biology, with a focus on understanding and manipulating DNA to stop cancer progression.
Unraveling the Mysteries of an Advanced Form of Prostate Cancer: Dr. Hui-Kuan Lin
Hui-Kuan Lin, MD, PhD, joined Duke Pathology in 2023, assuming the role of professor and director of Prostate Cancer Research.
Getting Creative with Gene Therapy to Improve Outcomes: Dr. Qianben Wang
Since joining Duke’s prostate cancer research team in 2017, Qianben Wang, PhD, has become a pivotal figure in the fight against prostate cancer. Initially focusing on regulatory mechanisms, Wang's journey has evolved into translational research, with a primary focus on developing cutting-edge gene therapies for prostate cancer.
Continuing Our Commitment: Equity, Diversity, and Inclusion Committee (EDI)
Guided by the leadership of EDI Vice Chair Danielle Elliott Range, MD, and Staff Director Kelly Macklin, our EDI Committee continues to make strides toward creating a welcoming environment for faculty, staff, and trainees with various perspectives and backgrounds.
A Pioneering Mentor: Robert Burgess Jennings
Robert Burgess Jennings, MD, a name synonymous with pioneering research and transformative leadership throughout Duke, retired in 2003, transitioning to his role as professor emeritus after a nearly six-decade career in cardiovascular research, 48 years of which he spent with Duke Pathology.